

Interview Summary	Application No.	Applicant(s)	
	09/642,405	NEEPER ET AL.	
	Examiner	Art Unit	
	Q. Janice Li	1632	

All participants (applicant, applicant's representative, PTO personnel):

(1) Q. Janice Li, PTO. (3) _____

(2) Alysia Finnegan, Appl. Rep. (4) _____

Date of Interview: 19 January 2004.

Type: a) ☒ Telephonic b) ☐ Video Conference
c) ☐ Personal [copy given to: 1) ☐ applicant 2) ☐ applicant's representative]

Exhibit shown or demonstration conducted: d) ☐ Yes e) ☒ No.
If Yes, brief description: _____

Claim(s) discussed: 1-4,6,7,10,11,15,17,18,20,22,23, and 30.

Identification of prior art discussed: N/A.


Agreement with respect to the claims f) ☒ was reached. g) ☐ was not reached. h) ☐ N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: _.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.



 Examiner's signature, if required

Continuation of Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: The Examiner indicated that claim 30 as written reads on making the HPV16 protein in a human subject, and thus genetic vaccination, which should have been included in the previous rejection of claims 24-26, 28 under §112, first paragraph. Ms. Finnegan agreed to the Examiner's suggestion to insert the phrase "an isolated" before "human host cell" in line 2. Ms. Finnegan also agreed to correct certain §112, 2nd paragraph issues of claims 1-4,6,7,10,11,15,17,18,20,22,23, and 30 by an Examiner's amendment to make the claims more clear.